CADL Earnings & Financial Statements
Candel Therapeutics, Inc.
$8.91
-$0.16(-1.76%)
36
Overall
60
Value
27
Tech
21
Quality
Market Cap
$694.02M
Volume
989.33K
52W Range
$4.35 - $14.00
Target Price
$21.75
CADL earnings and financial statements: Candel Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CADL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $125.0K | $100.0K |
| Operating income | -$48.27M | -$33.37M | -$38.39M | -$34.72M | -$25.73M |
| EBITDA | -$35.22M | -$52.10M | -$39.57M | -$16.31M | -$35.92M |
| Net income | -$38.18M | -$55.18M | -$37.94M | -$18.79M | -$36.12M |
| EPS (diluted) | $-0.72 | $-1.74 | $-1.31 | $-0.65 | $-1.91 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $125.19M | $106.87M | $41.20M | $77.69M | $89.20M |
| Total liabilities | $73.27M | $40.54M | $28.46M | $29.98M | $25.07M |
| Shareholders’ equity | $51.92M | $66.33M | $12.74M | $47.71M | $64.14M |
| Cash and equivalents | $119.73M | $102.65M | $35.41M | $70.06M | $82.64M |
| Long-term debt | $48.59M | $3.01M | $13.36M | $22.34M | $560.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$38.31M | -$27.02M | -$34.24M | -$31.42M | -$22.22M |
| Capital expenditure | -$560.0K | -$16.0K | -$457.0K | -$1.30M | -$1.83M |
| Free cash flow | -$38.90M | -$27.04M | -$34.70M | -$32.72M | -$24.05M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CADL | $8.91 | -1.8% | 989.33K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Candel Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW